Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aponermin + KT-DECP for relapsed multiple myeloma with plasmacytoma (real-world, multicenter)
ChiCTR2500102029Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Hospital, Capital Medical University
- Start
- May 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aponermin in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital, Capital Medical University. Primary endpoint: overall response rate. Started May 2025; status: recruiting.
02
Drugs
aponermin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500102029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102029.